Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Abstract: A platform software system enabling service station operators of unattended self-service devices to couple any number of self-service devices to a plurality of a point of sale station, regardless of the manufacture, without having to purchase additional integration hardware or incur customized development expenses. The system enables the operator to set promotions applicable to each self-service device in the form of tokens or configurable credit.

Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Abstract: The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

Abstract: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

Abstract: The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a PI3K inhibitor.

Abstract: The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a BTK inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a BTK inhibitor.

Abstract: A method of making a sheet structure comprising a first polycarbonate layer which comprises a UV-absorbing compound and a second polycarbonate layer comprises: (i) selecting a liquid formulation comprising a vehicle, for example a trimellitate or low molecular weight acrylic and an UV absorbing additive; and (ii) mixing the liquid formulation with polycarbonate when said first polymeric material is in a molten state, for example in an extruder.

Abstract: Apparatus for delivering a fluid to a location includes a means for supplying fluid connected to a reservoir. The reservoir has a variable volume and includes an outlet via which fluid may be delivered to the location.

Abstract: Apparatus for delivering a fluid to a location includes a mechanism for supplying fluid connected to a reservoir. The reservoir has a variable volume and includes an outlet via which fluid may be delivered to the location.

Abstract: Apparatus for delivering a fluid, especially for delivering colourants or the like to a premixer stage of plastics forming equipment, for example an injection moulder of extruder is described. The apparatus includes a fluid supply means (4, 200) connected to a reservoir (8, 208) which is arranged to concertina between minimum and maximum volume conditions. The reservoir (208) is connected via pipeline (24) and peristaltic pump (26) to a delivery means which is arranged to deliver the fluid to a desired location. When the fluid supply means (200) is empty, the level of fluid in the reservoir (208) will fall below the level of a capacitance sensor (32) which will sense the presence of air and cause a signal to be output to alert an operator to change fluid supply means (4). The fluid supply means may be changed before the reservoir is empty of fluid and, accordingly, the process may be operated continuously, even during the replacement of a reservoir (4).

Abstract: An apparatus including a network processor and a host system for monitoring packet communications on a packet network. The network processor captures all packets on a link of the network in real-time, to thereby capture communications transmitted via packet on the link. Each communication has at least one corresponding packet media stream. The host system communicates with the network processor to detect the packet media streams from the captured packets and to analyze the detected packet media streams.

Abstract: A host processor operating together with a network processor to detect packet media streams on a link of a packet network in accordance with a trigger. The network processor captures substantially all packets on the link in real-time to thereby capture communications transmitted via packets on the link. Each communication has at least one corresponding packet media stream. The host system communicates with the network processor to detect respective packet media streams from the captured packets in accordance with a trigger.

Abstract: A tap device comprises a network entry connection, a network exit connection, and a network interconnection path there between. A high impedance tap circuit is electrically connected to the network connection path, and comprises an isolation transformer and active buffer element. Advantageously, a power interruption to said tap circuit does not affect network communications.

Abstract: A host processor operating together with a network processor to detect packet media streams on a link of a packet network in accordance with a trigger. The network processor captures substantially all packets on the link in real-time to thereby capture communications transmitted via packets on the link. Each communication has at least one corresponding packet media stream. The host system communicates with the network processor to detect respective packet media streams from the captured packets in accordance with a trigger.